Xobesin agonists and antagonists for the treatment of metabolic disorders
    3.
    发明授权
    Xobesin agonists and antagonists for the treatment of metabolic disorders 失效
    Xobesin激动剂和拮抗剂用于治疗代谢紊乱

    公开(公告)号:US07276342B2

    公开(公告)日:2007-10-02

    申请号:US10485233

    申请日:2002-07-31

    IPC分类号: G01N33/53 C07K14/00 A61K38/00

    摘要: The present invention relates to the field of metabolic research, in particular the discovery of compounds effective for reducing body mass and useful for treating obesity-related diseases and disorders. The obesity-related diseases or disorders envisioned to be treated by the methods of the invention include, but are not limited to, hyperlipidemia, atherosclerosis, insulin resistance, diabetes, and hypertension. In particular, the invention provides for methods of identifying and using AGONISTS and ANTAGONISTS of XOBESIN activity, wherein said activity is selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity.

    摘要翻译: 本发明涉及代谢研究领域,特别涉及有效减少体重并可用于治疗与肥胖有关的疾病和病症的化合物的发现。 预期通过本发明的方法治疗的肥胖相关疾病或病症包括但不限于高脂血症,动脉粥样硬化,胰岛素抵抗,糖尿病和高血压。 特别地,本发明提供了鉴定和使用XOBESIN活性的AGONISTS和ANTAGONISTS的方法,其中所述活性选自脂质分配,脂质代谢和胰岛素样活性。

    Agonists and antagonists of prolixin for the treatrment of metabolic disorders
    6.
    发明申请
    Agonists and antagonists of prolixin for the treatrment of metabolic disorders 失效
    激素和拮抗剂,用于治疗代谢紊乱

    公开(公告)号:US20050069971A1

    公开(公告)日:2005-03-31

    申请号:US10496757

    申请日:2002-10-14

    摘要: The present invention relates to the field of metabolic research, in particular the discovery of compounds effective for reducing body mass and useful for treating obesity-related diseases and disorders. The obesity-related diseases or disorders envisioned to be treated by the methods of the invention include, but are not limited to, hyperlipidemia, atherosclerosis, insulin resistance, diabetes, and hypertension. In particular, the invention provides for methods of identifying and using AGONISTS and ANTAGONISTS of PROLIXIN activity, wherein said activity is selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity.

    摘要翻译: 本发明涉及代谢研究领域,特别涉及有效减少体重并可用于治疗与肥胖有关的疾病和病症的化合物的发现。 预期通过本发明的方法治疗的肥胖相关疾病或病症包括但不限于高脂血症,动脉粥样硬化,胰岛素抵抗,糖尿病和高血压。 特别地,本发明提供了鉴定和使用PROLIXIN活性的AGONISTS和ANTAGONISTS的方法,其中所述活性选自脂质分配,脂质代谢和胰岛素样活性。

    Agonists and antagonists of ryzn for the treatment of metabolic disorders
    9.
    发明申请
    Agonists and antagonists of ryzn for the treatment of metabolic disorders 审中-公开
    激动剂和ryzn的拮抗剂用于治疗代谢紊乱

    公开(公告)号:US20060089311A1

    公开(公告)日:2006-04-27

    申请号:US10496758

    申请日:2002-10-03

    IPC分类号: A61K38/06

    摘要: The present invention relates to the field of metabolic research, in particular the discovery of compounds effective for reducing body mass and useful for treating obesity-related diseases and disorders. The obesity-related diseases or disorders envisioned to be treated by the methods of the invention include, but are not limited to, hyperlipidemia, atherosclerosis, insulin resistance, diabetes, and hypertension. In particular, the invention provides for methods of identifying and using AGONISTS and ANTAGONISTS of RYZN activity, wherein said activity is selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity.

    摘要翻译: 本发明涉及代谢研究领域,特别涉及有效减少体重并可用于治疗与肥胖有关的疾病和病症的化合物的发现。 预期通过本发明的方法治疗的肥胖相关疾病或病症包括但不限于高脂血症,动脉粥样硬化,胰岛素抵抗,糖尿病和高血压。 特别地,本发明提供了鉴定和使用RYZN活性的AGONISTS和ANTAGONISTS的方法,其中所述活性选自脂质分配,脂质代谢和胰岛素样活性。

    Genobix agonists and antagonists for use in the treatment of metabolic disorders
    10.
    发明申请
    Genobix agonists and antagonists for use in the treatment of metabolic disorders 审中-公开
    用于治疗代谢紊乱的Genobix激动剂和拮抗剂

    公开(公告)号:US20070129291A1

    公开(公告)日:2007-06-07

    申请号:US10480699

    申请日:2002-07-30

    IPC分类号: A61K38/22

    摘要: The present invention relates to the field of metabolic research, in particular the discovery of compounds effective for reducing body mass and useful for treating obesity-related diseases and disorders. The obesity-related diseases or disorders envisioned to be treated by the methods of the invention include, but are not limited to, hyperlipidemia, atherosclerosis, insulin resistance, diabetes, and hypertension. In particular, the invention provides for methods of identifying and using AGONISTS and ANTAGONISTS of GENOBIX activity, wherein said activity is selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity.

    摘要翻译: 本发明涉及代谢研究领域,特别涉及有效减少体重并可用于治疗与肥胖有关的疾病和病症的化合物的发现。 预期通过本发明的方法治疗的肥胖相关疾病或病症包括但不限于高脂血症,动脉粥样硬化,胰岛素抵抗,糖尿病和高血压。 特别地,本发明提供鉴定和使用GENOBIX活性的AGONISTS和ANTAGONISTS的方法,其中所述活性选自脂质分配,脂质代谢和胰岛素样活性。